logo-loader
RNS
4basebio PLC

4basebio Plc - Final Results and Notice of AGM

Outlook


During 2025 and at the start of 2026, 4basebio has made substantial progress,positioningthe Company to capitalise on exciting opportunities ahead as next-generation genetic medicines market continuesitsrapid expansion.This is shown throughsignificant progress both in revenue and the development of its customer pipeline.

4basebio PLC

("4basebio" or the "Company")

Final Results and Notice of AGM

– 20 MayCAMBRIDGE, UK20264basebio plc (AIM: 4BB),–a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended .31 December 2025

FINANCIAL HIGHLIGHTS

OPERATIONAL HIGHLIGHTS

   POST-PERIOD END HIGHLIGHTS

Dr, Chief Executive Officer of 4basebio, commented:Amy Walker

“2025 represented a step-change for the Company, with GMP accreditation, a growing customer base and commercial appointments underpinning our transition into a highly commercially focused business. 4basebio’s expertise in enzymatic DNA manufacturing offers superior safety and efficacy compared with plasmid DNA, and we are seeing more advanced therapy developers recognising these advantages, underlined by the continued clinical use  of our technology.

“Since taking the role of CEO of 4basebio, I’ve been focused on putting the right team in place for this commercial phase and I’m excited by the progress we have achieved. We now have the personnel and infrastructure to drive delivery. After the period end, we’ve seen this reflected in strong commercial progress, enabled by a more diverse product offering and exceptional scientific and commercial teams. We believe 4basebio is extremely well positioned to benefit from the substantial and growing demand for synthetic DNA and accordingly we expect to see significant growth in revenues 2026 and beyond.”

Dr , Executive Chair of 4basebio, added:Manja Boerman

“4basebio is at a pivotal point in its development. We have a fantastic team in place, strengthening the Company’s ability to take advantage of the growing demand in genetic medicine markets for enzymatic manufacturing solutions.

“I want to thank our Board and share holders for their continued support. We are excited about the opportunities ahead and look forward to continuing to leverage our innovative offering, technical expertise and commercial infrastructure to drive further market penetration.”

This announcement contains inside information for the purposes of Article 7 of the version of the Market Abuse Regulation (EU) No. 596/2014 (“UK MAR”), as amended and forming part of law by virtue of the European Union (Withdrawal) Act 2018. Upon publication of this announcement, this inside information is now considered to be in the public domain.UKUK

Investor Presentation

The Company will host a presentation for institutional investors today at at the offices of RBC Capital Markets,09:00am100 Bishopsgate, EC2M 1GT. Investors who would like to attend can register their interestLondon.here

Annual Reports and Accounts and Notice of Annual General Meeting

The Annual Report and Accounts for the year ended , together with Notice of the Company’s Annual General Meeting, which is to be held on at at the offices of 4basebio plc, are expected to be uploaded to the Company’s website and posted to shareholders shortly.31 December 202530 June 202610:00am

The Annual General Meeting will be followed by a presentation from the Company through the Investor Meet Company platform. Further information will be provided in due course.

For further enquiries, please contact:

About 4basebio

4basebio (AIM: 4BB) is a -based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality. For more information, visitCambridge. www.4basebio.com

Joint statement from the Chief Executive Officer and Executive Chair

We are pleased to report on the year ended , which represented a pivotal year for 4basebio as we continued our transformation from a research-focused organisation into a commercially driven enterprise aiming to deliver synthetic, cell-free DNA as the foundation for every genetic medicine. While the advanced therapeutics sector faced challenging market conditions that impacted timelines and funding across the industry, we delivered significant operational progress that has positioned us strongly for accelerated growth.31 December 2025

During 2025, we continued to enhance and further innovate our product offering to address the growing demand of innovators working across multiple modalities including viral vectors, gene editing, mRNA medicines, DNA and mRNA for vaccines. These advancements diversified our customer base to more than 125 partners. The broad customer base now spans emerging and established biotechs and large pharmaceutical organisations. To date, we have supported four Investigational New Drug (IND) applications and Clinical Trial Authorisations (CTAs) underscoring our role as a trusted partner in advancing therapeutic development.

Regulatory Milestone Achievement

In , we achieved a critical regulatory milestone by securing MIA IMP Good Manufacturing Practice (GMP) certification from the Medicines and Healthcare products Regulatory Agency (MHRA). This certification authorises us to supply GMP-grade synthetic DNA for clinical programmes in advanced therapies and genetic medicines, cementing our capability to support partners throughout their entire clinical development lifecycle with premium, clinical-grade materials.April 2025UK's

Continued Clinical Validation

The clinical and commercial validation of our platform reached a significant milestone in October when a global Tier 1 pharmaceutical partner initiated patient dosing with an mRNA product utilising our proprietary opDNA® template in a Phase I/II clinical trial. This achievement, stemming from a supply agreement established in , demonstrates the real-world impact and reliability of our technology.April 2024

Strengthening Leadership for Scale

In , we appointed as Executive Chairman, a strategic addition that brings over 25 years of experience building multi-national CDMOs focused on biologics and advanced therapies. Manja's deep industry expertise and proven track record in scaling operations will be instrumental as we meet the escalating demand for our pDNA-free synthetic DNA platform.July 2025Manja Boerman

In the second half of the year, we established a new global commercial leadership team under , a 25-year life sciences veteran with exceptional experience building go-to-market operations for manufacturing services for advanced therapies or genetic medicines. Christine was promoted to Chief Commercial Officer in , and has accelerated our North American and European expansion in Business Development and Marketing activities leading to significant pipeline growth.Christine WolosinMarch 2026

Accelerating Commercial Momentum

Despite market headwinds, particularly from the US administration with regulatory concerns from FDA leadership and widespread cuts to the National Institute of Health’s budget, the Company delivered a 100% growth in DNA sales revenue. The impact of our strategic investments and new leadership additions became evident in the second half of 2025. Our new business pipeline value increased by 41% from Q3 to Q4 2025, reflecting strong market demand and the effectiveness of our enhanced commercial capabilities. This robust pipeline of pre-clinical and clinical opportunities, which has continued to expand post-period end, positions 4basebio for rapid commercial and financial growth in the years ahead.

New Chief Executive Officer and Chief Financial Officer

Post-period end in , Dr was appointed as Chief Executive Officer, after more than five years with the business, most recently as Chief Operating Officer. Amy played a key role in developing the IP surrounding the DNA platform and its application across the cell and gene therapy space, alongside scaling 4basebio’s GMP manufacturing capabilities, strengthening direct engagement with top-tier biopharma customers and supporting the Company’s growth operationally and strategically. Amy will lead the Company’s accelerated commercial growth strategy. Amy succeeded Dr Heikki Lanckriet, Founder of the Company, who has remained on the Board as a Non-Executive Director.February 2026Amy Walker

Following Amy’s transition to the role as CEO, 4basebio announced the appointment of as Chief Operating Officer. Scott brings more than 30 years’ experience in bioprocess development and scale up and clinical and commercial manufacturing of biologics and cell and gene therapies and will be responsible for scaling the Company’s innovative synthetic DNA platform as our commercial traction continues to accelerate.Scott Lorimer

was appointed CFO and will join the business in . Richard is an accomplished leader with over 30 years’ senior finance and strategic experience within the pharmaceutical and biotechnology sector, leading both public and private companies from research through all clinical phases, regulatory approval and commercialisation.Richard BungayJuly 2026

Financial performance

Overcoming some of the commercial headwinds arising in 2025 and with the commercial team demonstrating significant pipeline acceleration, the Group expects continued strong revenue growth in 2026. The Group expects to remain loss-making in 2026 and will draw on its cash resources to fund those losses.

Driving growth is the primary focus of the business. While the broader biotech fundraising environment and evolving US regulatory policies continue to present variable timelines for projects, the strong growth in commercial opportunities and pipeline demonstrates the rapidly growing demand for synthetic DNA whilst commercial visibility steadily improves. As a result, we anticipate continued acceleration in our pipeline and revenue though 2026 as clients continue to adopt cell-free DNA in their assets.

To support this commercial trajectory, 2026 will be a year of significant operational and product development. The Company’s confidence in its commercial success is underscored by the decision to relocate to a new innovation hub and manufacturing facility in , planned for late summer 2026, which will significantly expand our production footprint and increasing customer throughput.Cambridge, UK

Our vision is to become a worldclass manufacturer focused on delivering synthetic, cell-free DNA as the foundation for every genetic based medicine. 

While we anticipate continued strategic investments in our technologies and commercial infrastructure, the Board remains highly confident that these foundational steps will yield substantial, long-term shareholder and stakeholder value. We expect that our current cash levels will provide the Group with funding into late-2027.

We would like to take this opportunity to thank our shareholders for their continued support and our dedicated team for their exceptional work in delivering this transformational year. We look forward to much progress in the years ahead.

Dr                       DrManja BoermanAmy Walker
Executive Chair                              Chief Executive Officer

                                 19 May 202619 May 2026

Consolidated statement of profit or loss and other comprehensive income

For the year ended31 December 2025

All of the loss for the year is from continuing operations.

Consolidated statement of financial position

As at31 December 2025

Consolidated statement of changes in equity

For the years ended and31 December 202531 December 2024

Consolidated statement of cash flows

For the year ended31 December 2025

Notes to the financial statements

1. General

4basebio PLC (the “Company” or “4basebio”) is registered in and with company number 13519889. The Company is domiciled in and the registered office of the Company is , Over, CB24 5QE. 4basebio PLC is the parent of a group of companies (together, “the Group”). The Group focuses on life sciences, in particular the development of synthetic DNA and nanoparticles suitable for inclusion in, or delivery of, therapeutic payloads for gene therapies and gene vaccines.EnglandWalesEngland25 Norman WayCambridge

The Company trades on London Stock Exchange’s AIM market. The international securities number (ISIN) for its AIM-traded shares is GB00BMCLYF79; its ticker symbol is 4BB.L.

The consolidated financial statements of 4basebio PLC and its subsidiaries for the year ended were authorised for issue in accordance with a resolution of the Directors on .31 December 202519 May 2026

2. Basis of preparation

The consolidated financial statements of 4basebio PLC (“the Group”) for the financial year ended have been prepared in accordance with -adopted International Accounting Standards in conformity with the requirements of the Companies Act 2006.31 December 2025UK

The consolidated financial statements comprise the results of 4basebio PLC, 4basebio S.L.U., 4basebio UK Limited, 4basebio Discovery Limited and 4basebio Inc. (incorporated ) for the whole year (or, in the case of 4basebio Inc., from the date of incorporation).7 April 2025

The above summary has been extracted from the report and financial statements and, accordingly, references to notes and page numbers may be incorrect. Shareholders are advised to read the full version of the report and financial statements which will be available from the Company’s website shortly.

3. Earnings per share

The calculation of the basic and diluted loss per share for continuing operations was based on the weighted average number of shares as determined above. The numerator is the loss after tax from continuing operations. Outstanding share options have not been included in the calculation of the diluted loss per share because they would be anti-dilutive since the business is loss making.

4. Approval of the financial statements

The financial statements were approved by the Board of Directors and authorised for issue on .19 May 2026

--         Revenue for the period of £1.7 million (FY 2024: £0.9 million),
        representing growth of 81%, with revenue from clinical stage projects
        contributing £1.1 million (FY 2024: £0.5 million), and DNA sales revenue
        increasing by 100%
    --         Loss for the period of £16.9 million (FY 2024: £12.3 million),
        reflecting continued planned investment in commercial infrastructure,
        GMP capabilities and product development
    --         Cash and cash equivalents of £17.8 million at 
        (FY 2024: £34.6 million), with a subsequent €7 million drawdown under
        the Deutsche Balaton facility in  providing the Group with
        funding into late-202731 December 2025April 2026
--         Growing commercial momentum with a diverse and broadened customer
        base, driven by an expanding product offering focusing on gene editing,
        mRNA, viral vectors and DNA vaccines
    --         New business pipeline value increased by 41% from Q3 to Q4 2025,
        reflecting strong market demand and enhanced business development focus;
        approximately half of the pipeline is GMP/HQ opportunities, with
        momentum in new business continuing post-year end
    --         Receipt of MIA IMP Good Manufacturing Practice (GMP)
        certification from the UK’s Medicines and Healthcare Products Regulatory
        Agency (MHRA), significantly enhancing the Company’s ability to support
        customers through the clinical development lifecycle
        o        Tier 1 pharmaceutical partnership commenced, with supply of
          enzymatically-produced DNA for mRNA vaccine Phase I/II programme
    --           Customer base growth to 125+ customers, with four
        Investigational New Drug (IND) and Clinical Trial Authorisations (CTAs)
        supported
    --           Further clinical validation achieved through supply of opDNA™
        for an mRNA vaccine trial
    --         Appointment of senior, US and EU-focused commercial team
        experienced in genetic medicines and CDMO services, accelerating
        4basebio’s business development activity in 
    --           Expansion of intellectual property portfolio to 33 patent
        families, reinforcing 4basebio’s market leading position in synthetic
        DNANorth America
--          Dr  appointed as Executive Chair, bringing 25 years
        of experience in biologics and advanced therapies, including executive
        roles at Catalent’s cell, gene, and protein thearpy division, DSM
        Biologics, and Patheon BiologicsManja Boerman
--          Senior leadership team appointed to align 4basebio for
        acceleration of commercialisation, with the appointment of Dr 
        as Chief Executive Officer in 
    --           named Chief Financial Officer with a start date
        of 
    --           promoted to Chief Commercial Officer to lead
        global Business Development
    --          Appointment of , a 30-year veteran of bioprocess
        development and commercial manufacturing as Chief Operating Officer, to
        lead the building of 4basebio’s commercial infrastructure    -
    --         Signed a new multi-year, approximately seven-figure Clinical
        Supply Agreement reflecting increased commercial momentum, as 4basebio’s
        opDNA® technology will support a Phase II clinical trial of
        immunotherapy candidateAmy WalkerRichard BungayChristine WolosinScott LorimerFebruary 2026July 2026
4basebio PLC                                           +44 (0)12 2396 7943

    Dr , CEO

      Cairn Financial Advisers LLP (Nominated Adviser)     +44 (0)20 7213 0880

     /  / 

      Cavendish Capital Markets Limited (Joint Broker)     +44 (0)20 7220 0500

     / 

       RBC Capital Markets (Joint Broker)                  +44 (0)20 7653 4000

     / 

    ICR Healthcare (Media and Investor Relations)          +44 (0)203 707 5700

      /Amy WalkerJo TurnerSandy JamiesonEd DownesGeoff NashNigel BirksKathryn DeeganMatthew CoakesMary-Jane ElliottJessica Hodgson
[in £'000]                                         2025           2024

   Revenues                                           1,693          933

   Cost of goods sold                                 (719)          (303)

      Gross profit                                       974            630

   Administrative expenses                            (17,701)       (13,866)

   Other operating expenses                           (969)          (114)

   Other operating income                             96             1,308

      Operating result                                   (17,600)       (12,042)

   Finance income                                     884            140

   Finance costs                                      (887)          (752)

      Loss before tax                                    (17,603)       (12,654)

   Income tax credit                                  698            321

      Loss for the year                                  (16,905)       (12,333)

   Loss per share - basic and diluted (in £/share)    (1.09)         (0.94)

   Items that may be reclassified subsequently to
profit or loss:

   Foreign exchange differences on translation of     316            (313)
foreign operations

      Total comprehensive loss for the year              (16,589)       (12,646)
[in £'000]                          2025           2024

   Assets

   Other intangible assets             4,825          3,480

   Property, plant and equipment       4,027          4,326

   Other non-current assets            33             33

      Total non-current assets            8,885          7,839

   Current assets

   Inventory                           657            374

   Trade receivables                   289            283

   Other current assets                1,915          1,627

   Cash and cash equivalents           17,803         34,604

      Total current assets                20,664         36,888

      Total assets                        29,549         44,727

   Liabilities

   Trade payables                      (1,052)        (1,694)

   Lease liabilities                   (130)          (41)

   Other current liabilities           (1,607)        (1,383)

   Other financial liabilities         (39)           (147)

      Total current liabilities           (2,828)        (3,265)

   Non-current liabilities

   Financial liabilities               (15,645)       (14,294)

   Lease liabilities                   (691)          (734)

   Other liabilities                   (274)          (54)

      Total non-current liabilities       (16,610)       (15,082)

      Total liabilities                   (19,438)       (18,347)

      Net assets                          10,111         26,380

   Equity

   Share capital                       13,799         13,772

   Share premium                       37,254         37,250

   Capital reserves                    14,151         13,864

   Foreign exchange reserve            (155)          (471)

   Merger reserve                      688            688

   Accumulated losses                  (55,626)       (38,723)

      Total equity                        10,111         26,380
[in                                      FX                 P&L
£'000]        Share    Share   Capital   reserve  Merger    reserve   Total
              capital  premium reserve            reserve             equity

   At 1                           13,864    (471)    688                 26,380
January 2025  13,772   37,250                               (38,723)

   Loss for      -        -       -         -        -
the year                                                    (16,905)  (16,905)

   FX
translation      -        -       -         316      -         -         316
differences

   Shares
issued in        27       4       -         -        -         -         31
period
(SIP/options)


Share-based      -        -       288       -        -         -         288
payment
charge

      At 31                                             688
December 2025 13,799   37,254  14,151    (155)              (55,628)  10,111

   At 1                   706     13,530    (158)    688                 (492)
January 2024  11,132                                        (26,390)

   Loss for      -        -       -         -        -
the year                                                    (12,333)  (12,333)

   FX
translation      -        -       -         (313)    -         -         (313)
differences

   Shares
issued in        2,640 36,544     -         -        -         -         39,184
period


Share-based      -        -       334       -        -         -         334
payment
charge

      At 31                                             688
December 2024 13,772   37,250  13,864    (471)              (38,723)  26,380
[in £'000]                                         2025           2024

   Cash flows from operating activities

   Loss for the year                                  (16,905)       (12,333)

   Adjustments for:

   Tax charge                                         (698)          (321)

   Tax received                                       412            117

   Depreciation of property, plant and equipment      940            800

   Amortisation of capitalised development costs      205            133
and patents

   Share-based payment charge                         288            334

   Foreign exchange adjustments                       768            (608)

   Other operational foreign exchange and non-cash    411            (101)
items

   Net finance (income)/costs                         3              612

   Changes in working capital:

   (Increase)/decrease in inventories                 (283)          (49)

   (Increase)/decrease in trade receivables and       (294)          (76)
other current assets

   Increase/(decrease) in trade payables and other    (437)          748
current liabilities

      Net cash flow from operating activities            (15,588)       (10,744)

   Cash flows from investing activities

   Investments in property, plant and equipment       (458)          (697)

   Investments in capitalised development and         (1,181)        (874)
intangible assets

   Interest received                                  909            72

      Net cash flow from investing activities            (730)          (1,499)

   Cash flows from financing activities

   Proceeds from issue of equity (net of expenses)    -              38,484

   Proceeds from exercise of share options            31             700

   Drawdowns under loan facility                      -              8,800

   Repayments under loan facility                     (274)          (3,988)

   Lease liability repayments (IFRS 16)               (126)          (115)

   Interest paid                                      (72)           (86)

      Net cash flow from financing activities            (441)          43,795

   Net (decrease)/increase in cash and cash           (16,759)       31,552
equivalents

   Foreign exchange differences                       (42)           (17)

   Cash and cash equivalents at 1 January             34,604         3,069

      Cash and cash equivalents at 31 December           17,803         34,604
2025          2024

   Numerator [in £'000]

   Loss for the period                             (16,905)      (12,333)

   Denominator [number of shares]

   Weighted average number of registered shares    15,507,339    13,116,570

   Basic and diluted loss per share (£)            (1.09)        (0.94)



NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

35 min read